Mark Dybul Net Worth

Mark Dybul biography

Dr. Mark Dybul serves as Executive Vice Chairman of the Board, Principal Executive Officer of the Company. Dr. Dybul has served as a Professor in the Department of Medicine at Georgetown University Medical Center, and the Faculty Co-Director of the Center for Global Health and Quality since June of 2017. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University.

What is the salary of Mark Dybul?

As the Executive Vice Chairman of the Board és Principal Executive Officer of Enochian Biosciences Inc, the total compensation of Mark Dybul at Enochian Biosciences Inc is $1,964,450. There are no executives at Enochian Biosciences Inc getting paid more.

How old is Mark Dybul?

Mark Dybul is 57, he's been the Executive Vice Chairman of the Board és Principal Executive Officer of Enochian Biosciences Inc since 2019. There are 4 older and 4 younger executives at Enochian Biosciences Inc. The oldest executive at Enochian Biosciences Inc is Carol Brosgart, 69, who is the Independent Director.

What's Mark Dybul's mailing address?

Mark's mailing address filed with the SEC is 8974 BAYVIEW DRIVE,, , CHESTERTOWN, MD, 21620.

Insiders trading at Enochian Biosciences Inc

Over the last 7 years, insiders at Enochian Biosciences Inc have traded over $2,106,789 worth of Enochian Biosciences Inc stock and bought 552,919 units worth $3,888,612 . The most active insiders traders include Gregg H Alton, Rene Sindlev és Serhat Gumrukcu. On average, Enochian Biosciences Inc executives and independent directors trade stock every 91 days with the average trade being worth of $35,881. The most recent stock trade was executed by Serhat Gumrukcu on 18 May 2022, trading 253,493 units of ENOB stock currently worth $2,027,944.

What does Enochian Biosciences Inc do?

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.

Enochian Biosciences Inc executives and stock owners

Enochian Biosciences Inc executives and other stock owners filed with the SEC include:

• Mark Dybul,
  Executive Vice Chairman of the Board, Principal Executive Officer
• Luisa Puche,
  Chief Financial Officer
• Dr. Mark R. Dybul M.D.,
  Chief Exec. Officer & Director
• Luisa Puche,
  Chief Financial Officer
• Evelyn D'An,
  Independent Director
• James Sapirstein,
  Independent Director
• Carl Sandler,
  Independent Director
• Henrik Gronfeldt-Sorensen,
  Director
• Rene Sindlev,
  Independent Chairman of the Board
• Gregg Alton,
  Independent Director
• Carol Brosgart,
  Independent Director
• Dr. François Binette M.Sc., Ph.D.,
  Exec. VP for R&D
• Greg Duczynski Ph.D.,
  Sr. VP for Clinical Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Tung Nguyen,
  Head of Molecular Biology
• Dr. Wenshi Wang,
  Sr. VP of Operations
• Dr. Serhat Gümrükcü,
  Co-Founder & Inventor
• Francois Binette,
  Executive VP for R&D
• Jayne Mc Nicol,
  Director
• Eric Jean Marie Leire,,
  
• Carl Forest Sandler,
  
• Serhat Gumrukcu,
  10% owner
• Anderson Wittekind William,
  
• Science Llc Weird,